TORONTO, June 29 /CNW/ - Biosign Technologies Inc. (CNSX:BIO) ("Biosign" or the "Company") reports the results of Annual General and Special Shareholder Meeting ("AGM") held on June 28th, 2010.
Shareholders approved the re-election of Radu Leca, David Silver, and Tony LaVista as directors of Biosign, and the election of Mouane Sengsavang as a new director for the ensuing year. Ms. Sengsavang, a principal of Buttonwood Law Corporation, is a securities lawyer who is called to the Bar in British Columbia and Alberta. The Board welcomes Ms. Sengsavang, and believes that shareholders shall benefit from her experience in securities matters and attention to corporate governance.
Shareholder approval was received to appoint Collins Barrow Toronto, LLP as auditor of the Corporation for the ensuing year and to authorize the directors to fix the auditors' remuneration.
Shareholder approval was received to authorize the independent directors to issue up to 25% of the existing share capital to finance the acquisition of companies, businesses or assets that the independent directors identify as being strategically important to the Corporation.
Shareholder approval was received to empower the directors of the company to determine the number of directors of the Company from time to time and to appoint a person or persons to cover any vacancy or vacancies on the board of directors resulting from any increase in the number of directors.
At the AGM, it was reported that shareholders approved a special resolution to authorize the independent directors to consolidate the shares of the company, if deemed necessary. Upon further examination, the Scrutineer ascertained that he had received incomplete proxies and that the resolution had not achieved the required 66.67% of votes cast. The Board recognizes that, in certain cases, a share consolidation may be beneficial to shareholders and, should such an opportunity arise, will bring the matter to the shareholders for approval.
Additional details will be included in the Company's monthly report for June 2010.
ON BEHALF OF THE BOARD OF DIRECTORS
Radu Leca, President & CEO
Phone: (416) 218-9800 ext. 234
About Biosign Technologies Inc.
Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information please visit www.biosign.com
The CNSX has neither approved nor disapproved the contents of this press release.
SOURCE Biosign Technologies Inc.
For further information: For further information: Radu Leca, President & CEO, Phone: (416) 218-9800 ext. 234, Email: email@example.com